Secondary prophylaxis after hip fracture: hospital-based zoledronate versus primary care-based denosumab

Phase 4, open-label trial of zoledronate and denosumab in osteoporosis and hip fracture (2 arms), sponsored by Akershus University Hospital. Primary endpoint: Assessment of applicability and feasibility of medical fracture prophylaxis after hip fracture in patients alive after 6 weeks in a real-life setting. Started Mar 2015; status: terminated.